Clinical Trials Using Trastuzumab Emtansine

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trastuzumab Emtansine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-13 of 13
  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1170 locations

  • I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
    Location: 14 locations

  • Docetaxel, Cisplatin, and Fluorouracil in Treating Patients with Gastric or Gastroesophageal Junction Cancer That is Metastatic or Cannot Be Removed by Surgery

    This randomized phase II trial studies how well docetaxel, cisplatin, and fluorouracil work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 10 locations

  • Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer

    This phase II trial studies how well trastuzumab emtansine and pertuzumab before surgery work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive stage II-III breast cancer. HER2 is a protein found on the surface of cancer cells that helps them to grow and spread. Trastuzumab emtansine and pertuzumab may kill cancer cells by binding to HER2-positive on the surface of the tumor cells and blocking their ability to grow and spread.
    Location: 8 locations

  • Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

    This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer.
    Location: 8 locations

  • A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

    This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech / Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.
    Location: 6 locations

  • Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer

    This phase Ib trial studies the side effects and best dose of taselisib when given with anti-human epidermal growth factor receptor 2 (HER2) therapies in treating patients with HER2 positive (HER2+) breast cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Taselisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab emtansine, pertuzumab, and trastuzumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Antihormone therapy, such as fulvestrant, may lessen the amount of estrogen made by the body. It is not yet known whether taselisib works better when given together with trastuzumab emtansine, pertuzumab, and trastuzumab, or with pertuzumab, trastuzumab, paclitaxel, and fulvestrant in treating patients with breast cancer.
    Location: 5 locations

  • Pembrolizumab and Trastuzumab Emtansine in Treating Patients with Metastatic HER2-Positive Breast Cancer

    This phase Ib trial studies the side effects and best way to give pembrolizumab and trastuzumab emtansine in treating patients with HER2-positive breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab and trastuzumab emtansine, may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

    This phase Ib / II trial studies the side effects and best dose of ribociclib with trastuzumab or trastuzumab emtansine and to see how well they work in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or other places in the body and is human epidermal growth factor receptor 2 (HER2)-positive. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, block tumor growth in different ways by targeting certain cells. Immunotoxins, such as trastuzumab emtansine, are antibodies linked to a toxic substance and may help find tumor cells and kill them without harming normal cells. Giving ribociclib with trastuzumab emtansine or trastuzumab may work better in treating patients with breast cancer.
    Location: 3 locations

  • Trastuzumab Emtansine with or without Temozolomide in Preventing Development of Brain Metastases after Stereotactic Radiosurgery in Patients with HER2 Positive Brea t Cancer

    This randomized phase I / II trial studies the side effects and best dose of temozolomide when given together with trastuzumab emtansine and how well they work in preventing the development of brain metastases after stereotactic radiosurgery in patients with HER2 positive breast cancer. Monoclonal antibodies, such as trastuzumab emtansine, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving temozolomide and trastuzumab emtansine may work better in preventing development of brain metastases in patients with breast cancer.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Trastuzumab Emtansine in Treating Patients with HER2 Amplified or Mutant Advanced Cancers

    This phase II trial studies how well trastuzumab emtansine works in treating patients with human epidermal growth factor receptor 2 (HER2) amplified or HER2 mutant cancers, including lung and bladder, that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Monoclonal antibodies, such as trastuzumab emtansine, may block tumor growth in different ways by targeting certain cells.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

    This study is being done for the following reasons: - The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of neratinib that can be given safely with T-DM1. - The purpose of the second part of the study (Phase II) is to find out whether the dose of neratinib with T-DM1 determined in Phase I will keep breast cancer from getting worse for a period of time. - In order to learn more about study therapy levels in blood and discover genetic and protein changes associated with cancer, the study includes special research tests using samples from blood and from breast tumor. Blood samples will be collected before study treatment, once during treatment, and after study treatment stops. - In the optional part of this study, three biopsies will be performed to obtain fresh tumor samples from an area where your cancer has spread.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer

    This phase I clinical trial studies the side effects and the best dose of palbociclib isethionate (palbociclib) when given together with ado-trastuzumab emtansine (trastuzumab emtansine) in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has returned or has spread to other parts of the body. Palbociclib may work by suppressing the ability of treatment resistant tumors to expand or grow. Trastuzumab emtansine may work by finding HER-2 positive breast cancer cells and killing them. Giving palbociclib and trastuzumab emtansine may work better in treating HER2-positive breast cancer.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas